Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies

This study is a prospective, non-randomized feasibility study of drug response profiling (DRP) in pediatric blood cancers. Primary cancer cells are isolated from patients and screened ex vivo at single-cell resolution using automated fluorescence microscopy. Drug sensitivity fingerprints are integrated with genetic annotations to inform the treating physician about personalized treatment options. The study aims to determine the practicability of real-time drug response profiling and its actionability in identifying patient-specific cancer dependencies in refractory disease settings.

NCT Number	NCT06550102
Lead Sponsor	University Children's Hospital, Zurich
Conditions	Hematological Malignancies
Enrollment	1,000 participants
Start Date	2022-01-04
Primary Completion	2031-12-31 (estimated)
Study Completion	2031-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-15